A Study to Evaluate the Safety and Tolerability of Immunotherapy Combinations in Participants With Advanced Malignancies

NCT03629756 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

48

Enrollment

INDUSTRY

Sponsor class

Conditions

Non-small Cell Lung Cancer
Squamous Cell Carcinoma of the Head and Neck
Breast Cancer
Colorectal Cancer
Melanoma
Bladder Cancer
Ovarian Cancer
Endometrial Cancer
Merkel Cell Carcinoma
GastroEsophageal Cancer
Renal Cell Carcinoma
Castration-resistant Prostate Cancer

Interventions

DRUG: Etrumadenant
DRUG: Zimberelimab

Sponsor

Arcus Biosciences, Inc.